News

Gilead filed a new drug application for the treatment, a combination of the company’s Sovaldi with velpatasvir, in October last year. A final decision from the FDA is

The immuno-oncology collaboration intends to advance development of novel immune checkpoint therapies. Baxalta agreed to make an upfront payment of $175m to Symphogen in exchange for exclusive rights

The companies have signed a collaboration agreement under which Pfizer and Merck will combine their avelumab cancer drug with Syndax’s entinostat, a treatment currently being studied in patients

PIKA rabies vaccine is an innovative rabies vaccine independently developed by Yisheng Biopharma, using a novel double-strand RNA analog ("PIKA") which acts as a toll-like receptor-3 (TLR-3) agonist

Auxilium has provided its contractually obligated six-month notice of termination which, absent an agreement between Auxilium and VIVUS for an earlier date, will result in the termination of

This new strategic collaboration is expected to leverage the expertise of Araim Pharmaceuticals in scientific discovery and research with Vault Bioventures’ proven capability in clinical and regulatory development

Under the terms of the agreement with Acerus, Endo will continue to sell and distribute Natesto in the US until the effective date of termination. Acerus president and

Preeclampsia is one of the most common medical complications of pregnancy, and a leading cause of premature births, stillbirths and early neonatal and maternal deaths. Severe preeclampsia occurs

GBT440 is an oral, once-daily SCD therapy that works by increasing hemoglobin’s affinity for oxygen. The company is investigating the drug candidate in both healthy subjects and SCD